从成年囊性纤维化（CF）患者中分离出的野生型临床铜绿假单胞菌对TOBI和BRAMITOB（妥布霉素吸入溶液）的体外敏感性直接比较。 - Suppr

Suppr

超能文献

Direct comparison of in vitro susceptibility of wildtype clinical Pseudomonas aeruginosa isolated from adult patients with cystic fibrosis (CF) to TOBI and BRAMITOB (tobramycin inhalation solutions).

作者信息

Moore John E, Maeda Yasunori, Goldsmith Colin E, Rendall Jacqueline C, Elborn J Stuart

出版信息

J Cyst Fibros. 2010 May;9(3):237-8. doi: 10.1016/j.jcf.2010.03.005. Epub 2010 Apr 7.

DOI:10.1016/j.jcf.2010.03.005

PMID:20378421

Abstract

摘要

相似文献

Direct comparison of in vitro susceptibility of wildtype clinical Pseudomonas aeruginosa isolated from adult patients with cystic fibrosis (CF) to TOBI and BRAMITOB (tobramycin inhalation solutions).

J Cyst Fibros. 2010 May;9(3):237-8. doi: 10.1016/j.jcf.2010.03.005. Epub 2010 Apr 7.

Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis.

J Infect Dis. 1999 May;179(5):1190-6. doi: 10.1086/314727.

Colistin-tobramycin combinations are superior to monotherapy concerning the killing of biofilm Pseudomonas aeruginosa.

J Infect Dis. 2010 Nov 15;202(10):1585-92. doi: 10.1086/656788. Epub 2010 Oct 13.

Routine susceptibility tests with ticarcillin and tobramycin in combination should be more appropriate than with each antibiotic alone in cystic fibrosis Pseudomonas aeruginosa.

J Chemother. 1989 Jul;1(4 Suppl):184-6.

Clinical pharmacology study of Bramitob, a tobramycin solution for nebulization, in comparison with Tobi.

Paediatr Drugs. 2007;9 Suppl 1:3-9. doi: 10.2165/00148581-200709001-00002.

Budget impact model of tobramycin inhalation solution for treatment of Pseudomonas aeruginosa in cystic fibrosis patients.

J Med Econ. 2010;13(3):492-9. doi: 10.3111/13696998.2010.505863.

Antimicrobial susceptibility of Pseudomonas aeruginosa before and after initiation of inhaled tobramycin in Bulgaria.

J Infect Dev Ctries. 2016 Nov 24;10(11):1265-1267. doi: 10.3855/jidc.7658.

Comparison of antibiotic susceptibility patterns in Pseudomonas aeruginosa isolated from adult patients with cystic fibrosis (CF) with invasive Pseudomonas aeruginosa from non-CF patients.

J Cyst Fibros. 2012 Jul;11(4):349-52. doi: 10.1016/j.jcf.2012.01.002. Epub 2012 Feb 9.

Tobramycin Inhalation Powder™: a novel drug delivery system for treating chronic Pseudomonas aeruginosa infection in cystic fibrosis.

Expert Rev Respir Med. 2011 Oct;5(5):609-22. doi: 10.1586/ers.11.56.

Antimicrobial activity of tobramycin against respiratory cystic fibrosis Pseudomonas aeruginosa isolates from Bulgaria.

J Chemother. 2010 Dec;22(6):378-83. doi: 10.1179/joc.2010.22.6.378.

引用本文的文献

Inhaled Antibiotics for Gram-Negative Respiratory Infections.

Clin Microbiol Rev. 2016 Jul;29(3):581-632. doi: 10.1128/CMR.00101-15.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Direct comparison of in vitro susceptibility of wildtype clinical Pseudomonas aeruginosa isolated from adult patients with cystic fibrosis (CF) to TOBI and BRAMITOB (tobramycin inhalation solutions).

作者信息

Moore John E, Maeda Yasunori, Goldsmith Colin E, Rendall Jacqueline C, Elborn J Stuart

出版信息

J Cyst Fibros. 2010 May;9(3):237-8. doi: 10.1016/j.jcf.2010.03.005. Epub 2010 Apr 7.

DOI:10.1016/j.jcf.2010.03.005

PMID:20378421

Abstract

摘要